Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements

dc.creatorPandey, Abhjieet
dc.creatorNitin Nikam, Ajinkya
dc.creatorBasavaraj Shreya, Ajjappla
dc.creatorMutalik, Sadhana P.
dc.creatorGopalan, Divya
dc.creatorKulkarni, Sanjay
dc.creatorSingh Padya, Bharath
dc.creatorFernandes, Gasper
dc.creatorMutalik, Srinivas
dc.creatorPrassl, Ruth
dc.date.accessioned2020-08-10T13:51:30Z
dc.date.available2020-08-10T13:51:30Z
dc.date.created2020
dc.description.abstractThe present pandemic of SARS-CoV-2 has been a tough task for the whole world to deal with. With the absence of specific drugs or vaccines against SARS-CoV-2, the situation is very difficult to control. Apart from the absence of specific therapies, the lack of knowledge about potential therapeutic targets and individual perception is adding to the complications. The present review describes the novel SARS-CoV-2 structure, surface proteins, asymptomatic and symptomatic transmission in addition to the genotype and phenotype of SARS-CoV-2 along with genetic strains and similarity between SARS, MERS and SARS-CoV-2. Therapeutic strategies such as inhibition of the endocytic pathway and suppressing RNA polymerase activity by metal ions, which could be quite beneficial for controlling COVID-19, are outlined. The drug repurposing for SARS-CoV-2 is discussed in detail along with therapeutic classes such as antivirals, antibiotics, and amino quinolones and their probable role in suppressing SARS-CoV-2 with reference to case studies. The ongoing clinical trials both with respect to drug repurposing and vaccines are summarized along with a brief description. The recent advancements and future perspective of ongoing research for therapy and detection of SARS-CoV-2 are provided. The review, in brief, summarizes epidemiology, therapy and the current scenario for combating SARS-CoV-2spa
dc.format.extent20 páginasspa
dc.format.mimetypeimage/jepgspa
dc.identifier.doihttps://doi.org/10.1016/j.lfs.2020.117883spa
dc.identifier.issn0024-3205spa
dc.identifier.otherhttps://doi.org/10.1016/j.lfs.2020.117883spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/11757
dc.publisherLife Sciencesspa
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccessspa
dc.rights.localAcceso restringidospa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectSARS-CoV-2spa
dc.subjectDrug repurposingspa
dc.subjectClinical trialsspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titlePotential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancementsspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 2 de 2
Cargando...
Miniatura
Nombre:
Captura.PNG
Tamaño:
160.08 KB
Formato:
Portable Network Graphics
Descripción:
Ver portada
Cargando...
Miniatura
Nombre:
Potential-therapeutic-targets-for-combating-SARS-CoV-2--Drug-re_2020_Life-Sc.pdf
Tamaño:
1.26 MB
Formato:
Adobe Portable Document Format
Descripción:
Artículo reservado

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción: